In HER2-negative patients with gastric cancer, first-line chemotherapy plus anti-PD-1 inhibitor treatment showed a survival benefit in the ATTRACTION-4 (progression-free survival, PFS) and CheckMate-649 (PFS and overall survival, OS) trials10,11 when compared with chemotherapy alone. The gene discussed is ERBB2; the disease is gastric cancer.